Enzo Biochem, Inc. Quarterly report pursuant to Section 13 or 15(d)

Segment Reporting (Tables)

3 Months Ended

Oct. 31, 2022

Three months ended October 31, 2022	Clinical Services			Products			Other			Consolidated
Revenues	$	11,173		$	7,103			—		$	18,276

Operating costs and expenses:
Cost of revenues		10,082			4,589			—			14,671
Research and development		297			690			9			996
Selling, general and administrative		6,550			2,430			2,471			11,451
Legal fee expense		64			25			982			1,071
Total operating costs and expenses		16,993			7,734			3,462			28,189

Operating loss		(5,820	)		(631	)		(3,462	)		(9,913	)

Other income (expense):
Interest, net		(2	)		25			47			70
Other		5			2			(2	)		5
Foreign exchange loss		—			(797	)		—			(797	)
Net loss	$	(5,817	)	$	(1,401	)	$	(3,417	)	$	(10,635	)

Depreciation and amortization included above	$	532			165			83			780

Share-based compensation included in above:
Selling, general and administrative		48			20			340			408
Cost of revenues		16			6			—			22
Total	$	64			26			340			430

Capital expenditures	$	163			306			183			652

Three months ended October 31, 2021	Clinical Services			Products			Other			Consolidated
Revenues	$	19,741		$	6,778			—		$	26,519

Operating costs and expenses:
Cost of revenues		11,203			4,070			—			15,273
Research and development		7			732			5			744
Selling, general and administrative		6,001			3,095			1,956			11,052
Legal fee expense		57			13			1,212			1,282
Total operating costs and expenses		17,268			7,910			3,173			28,351

Operating income (loss)		2,473			(1,132	)		(3,173	)		(1,832	)

Other income (expense):
Interest, net		(2	)		9			32			39
Other		49			2			(196	)		(145	)
Foreign exchange loss		—			(381	)		—			(381	)
Net income (loss)	$	2,520		$	(1,502	)	$	(3,337	)	$	(2,319	)

Depreciation and amortization included above	$	418			212			71			701

Share-based compensation included in above:
Selling, general and administrative		20			19			173			212
Cost of revenues		4			—			—			4
Total	$	24			19			173			216

Capital expenditures	$	310			486			237			1,033